Role Of Phospholipid Transfer Proteins (Pltp) On Endotoxemia Caused By Buccal Inflammation (TOXIB)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This is a transversal double-centre study. Patients will be recruited from outpatient consultations. They will have buccal inflammation caused by periodontal disease (frequent oral infections, mostly with GRAM (-) bacteria). Three groups of 80 patients, corresponding to slight, moderate and severe periodontal disease, will be formed according to the results of radiological and clinical examinations.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
35 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Persons aged from 35 to 80 years old
Persons who have provided written informed consent
Patients with periodontal disease whatever the severity with at least one molar or one premolar on the dental arch
Possibility to examine the oral cavity (patient able to open mouth)
Possibility to do an orthopantomogram (sitting position required and patient able to clench jaws)
Patient able to understand French
Patient who accepts to provide fasting blood sample within the five days following the initial consultation
DEFINITIVE INCLUSION CRITERIA
- Patient present for the fasting blood sample within five days following the initial consultation Patients will be matched for sex and, as much as possible, for age in the three groups and for the severity of the periodontal disease
Persons not covered by the national health insurance agency
Patients with a high risk of infectious endocarditis who require prophylaxis for any medical act involving blood
Patients who have taken at least once during the 8 days preceding the definitive inclusion an anti-inflammatory dose of NSAIDS and/or a salicylate (blood sample)
Patients who have had long-term treatment (>6 months) with corticoids at a dose of at least 15 mg per day
Patients on antibiotics less than 15 days before the blood sample
Patients with oral inflammation requiring treatment with antibiotics or anti-inflammatory drugs during the pre-inclusion
Scaling during the 24 hours before the blood sample
History of oral cancer or cancer of the pharynx
Active cancer (patient undergoing treatment or diagnosis within the previous 5 years)
Iatrogenic, spontaneous or therapeutic immunodepression (patient on immunosuppressants or antiretrovirals),
Systemic or organ specific inflammatory syndrome not related to the periodontal disease
proven bacterial, viral or fungal Infection either developing or being treated (urinary, prostate infection)
Inflammatory cancer (solid tumour, malignant hemopathy)
Impossibility to cooperate due to a psychiatric disease, dementia